In a 61‑year‑old woman with type 2 diabetes, hypertension and hyperlipidemia who is taking metformin 1000 mg twice daily, glipizide 10 mg twice daily, a sliding‑scale of insulin aspart three times daily, insulin glargine (Lantus) 15 units nightly (held if pre‑prandial glucose <110 mg/dL), and dulaglutide (Trulicity) 0.75 mg weekly, and whose most recent hemoglobin A1c is 8.4 %, what is the next step in her diabetes management?

Immediate Discontinuation of Glipizide and Aggressive Insulin Intensification Required

This patient's HbA1c of 8.4% on a complex five-drug regimen including both basal and prandial insulin indicates therapeutic failure; the sulfonylurea (glipizide) must be stopped immediately to prevent severe hypoglycemia, and the insulin doses require aggressive titration to achieve glycemic control. 1

---

Critical Problem: Sulfonylurea + Insulin = Dangerous Combination

• Glipizide 10 mg BID must be discontinued immediately when a patient is already receiving both basal (Lantus 15 units) and prandial insulin (aspart sliding scale TID), because continuing a sulfonylurea with insulin markedly raises severe hypoglycemia risk. 1
• The UK Prospective Diabetes Study demonstrated that adding metformin to a sulfonylurea regimen was associated with a statistically significant increase in diabetes-related mortality (P = 0.039), and sulfonylureas combined with insulin produce hypoglycemic events in approximately 30% of patients per year versus only 1% in standard-treatment arms. 1
• Sulfonylureas rank as the fourth leading cause of emergency-room admissions for drug-related side effects in adults > 65 years, and this 61-year-old patient faces unacceptable risk. 1

---

Insulin Regimen Is Profoundly Inadequate

• Lantus 15 units nightly is grossly insufficient for a patient with HbA1c 8.4%; the recommended starting dose for insulin-naïve type 2 diabetes patients is 10 units once daily or 0.1–0.2 units/kg/day, and this patient clearly requires aggressive titration beyond the starting dose. 1, 2
• The "hold if BG < 110" instruction is inappropriate and contributes to under-dosing; basal insulin should be titrated to achieve fasting glucose 80–130 mg/dL, not held at 110 mg/dL. 1
• Sliding-scale insulin aspart TID as the sole prandial coverage is condemned by all major diabetes guidelines as reactive rather than preventive therapy, achieving target glucose in only ~38% of patients versus ~68% with scheduled basal-bolus regimens. 1

---

Immediate Medication Changes

1. Stop Glipizide Immediately

• Discontinue glipizide 10 mg BID today to eliminate the 7-fold increased hypoglycemia risk when sulfonylureas are combined with insulin. 1

2. Aggressive Basal Insulin Titration

• Increase Lantus by 4 units every 3 days until fasting glucose consistently reaches 80–130 mg/dL; this patient likely needs 30–40 units (approximately 0.5 units/kg for a typical adult) to achieve adequate basal coverage. 1, 2
• Remove the "hold if BG < 110" instruction; basal insulin should only be held if glucose falls < 70 mg/dL. 1
• When the Lantus dose approaches 0.5 units/kg/day (roughly 35–40 units for most adults) without achieving HbA1c < 7%, stop further basal escalation and focus on prandial insulin intensification to avoid "over-basalization." 1

3. Convert Sliding-Scale to Scheduled Prandial Insulin

• Replace the sliding-scale aspart TID with scheduled prandial insulin: start 4 units of insulin aspart before each of the three largest meals (breakfast, lunch, dinner), administered 0–15 minutes before eating. 1
• Add correction doses on top of scheduled prandial insulin: give an additional 2 units for pre-meal glucose > 250 mg/dL and 4 units for > 350 mg/dL. 1
• Titrate each meal dose by 1–2 units every 3 days based on 2-hour post-prandial glucose readings, targeting < 180 mg/dL. 1

4. Optimize Metformin Dosing

• Increase metformin to 2000 mg daily (1000 mg BID with meals) if the patient is currently taking less; metformin reduces total insulin requirements by 20–30% and provides superior glycemic control when combined with insulin. 1, 3
• The maximum effective dose is 2000–2550 mg daily, and doses above 2000 mg add minimal benefit while increasing gastrointestinal intolerance. 1

5. Continue Dulaglutide (Trulicity)

• Maintain dulaglutide 0.75 mg weekly for its proven cardiovascular benefit and additional HbA1c reduction of 0.6–0.8% when combined with insulin. 4, 1
• GLP-1 receptor agonists like dulaglutide promote 2–5 kg weight loss and carry minimal hypoglycemia risk when sulfonylureas are discontinued. 4, 1

---

Expected Clinical Outcomes

• With properly implemented basal-bolus therapy (scheduled Lantus + scheduled aspart before meals), approximately 68% of patients achieve mean glucose < 140 mg/dL, compared with only 38% using inadequate sliding-scale approaches. 1
• HbA1c reduction of 1.5–2.0% is achievable within 3–6 months with aggressive insulin titration combined with metformin, potentially bringing this patient's HbA1c from 8.4% to < 7.0%. 1
• Discontinuing glipizide will dramatically reduce hypoglycemia risk while allowing safe insulin intensification. 1

---

Monitoring Requirements

• Daily fasting glucose checks during the first 2–3 weeks of Lantus titration to guide dose adjustments. 1, 2
• Pre-meal glucose before each meal to calculate correction doses. 1
• 2-hour post-prandial glucose after each meal to assess prandial insulin adequacy and guide titration. 1
• Reassess HbA1c at 3 months after regimen changes; this is the longest acceptable interval before evaluating effectiveness and avoiding therapeutic inertia. 1

---

Critical Pitfalls to Avoid

• Never continue glipizide when a patient is on both basal and prandial insulin; the combination produces a 7-fold increase in severe hypoglycemia and lacks cardiovascular benefit. 1
• Do not delay insulin intensification when HbA1c is 8.4% on a five-drug regimen; prolonged hyperglycemia increases complication risk. 1
• Never rely solely on sliding-scale insulin without scheduled basal and prandial doses; this reactive approach is condemned by major diabetes guidelines and achieves target glucose in only ~38% of patients. 1
• Do not discontinue metformin when intensifying insulin; the combination reduces insulin requirements by 20–30% and provides superior outcomes. 1, 3
• Avoid continuing basal insulin escalation beyond 0.5–1.0 units/kg/day without addressing post-prandial hyperglycemia, as this leads to "over-basalization" with increased hypoglycemia risk. 1

---

Summary Algorithm

1. Today: Stop glipizide 10 mg BID immediately. 1
2. Today: Increase Lantus from 15 units to 20 units nightly (remove "hold if BG < 110" instruction). 1, 2
3. Today: Replace sliding-scale aspart with scheduled 4 units aspart before each meal + correction doses (2 U for glucose > 250 mg/dL, 4 U for > 350 mg/dL). 1
4. Today: Optimize metformin to 1000 mg BID (2000 mg total daily). 1
5. Every 3 days: Increase Lantus by 4 units until fasting glucose reaches 80–130 mg/dL. 1
6. Every 3 days: Increase each meal's aspart dose by 1–2 units based on 2-hour post-prandial glucose, targeting < 180 mg/dL. 1
7. 3 months: Recheck HbA1c; target < 7.0%. 1